These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 12927306

  • 21. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
    Cundy KC.
    Clin Pharmacokinet; 1999 Feb; 36(2):127-43. PubMed ID: 10092959
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro.
    Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, Hostetler KY.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):656-62. PubMed ID: 15673748
    [Abstract] [Full Text] [Related]

  • 23. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.
    Keith KA, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, Kern ER.
    Antimicrob Agents Chemother; 2004 May; 48(5):1869-71. PubMed ID: 15105146
    [Abstract] [Full Text] [Related]

  • 24. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
    Trost LC, Rose ML, Khouri J, Keilholz L, Long J, Godin SJ, Foster SA.
    Antiviral Res; 2015 May; 117():115-21. PubMed ID: 25746331
    [Abstract] [Full Text] [Related]

  • 25. Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.
    Ma F, Nan K, Lee S, Beadle JR, Hou H, Freeman WR, Hostetler KY, Cheng L.
    Eur J Pharm Biopharm; 2015 Jan; 89():271-9. PubMed ID: 25513956
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
    Israely T, Paran N, Lustig S, Erez N, Politi B, Shafferman A, Melamed S.
    Virol J; 2012 Jun 18; 9():119. PubMed ID: 22709563
    [Abstract] [Full Text] [Related]

  • 28. Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
    Bravo FJ, Bernstein DI, Beadle JR, Hostetler KY, Cardin RD.
    Antimicrob Agents Chemother; 2011 Jan 18; 55(1):35-41. PubMed ID: 21078944
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits.
    Cundy KC, Li ZH, Lee WA.
    Drug Metab Dispos; 1996 Mar 18; 24(3):315-21. PubMed ID: 8820422
    [Abstract] [Full Text] [Related]

  • 32. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice.
    Smee DF, Bailey KW, Wong MH, Wandersee MK, Sidwell RW.
    J Infect Dis; 2004 Sep 15; 190(6):1132-9. PubMed ID: 15319864
    [Abstract] [Full Text] [Related]

  • 33. Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.
    Wang H, Chhablani J, Freeman WR, Beadle JR, Hostetler KY, Hartmann K, Conner L, Aldern KA, Pearson L, Cheng L.
    Invest Ophthalmol Vis Sci; 2011 Dec 09; 52(13):9391-6. PubMed ID: 22058340
    [Abstract] [Full Text] [Related]

  • 34. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
    Smee DF, Bailey KW, Sidwell RW.
    Chemotherapy; 2003 Jun 09; 49(3):126-31. PubMed ID: 12815205
    [Abstract] [Full Text] [Related]

  • 35. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).
    Lalezari JP, Stagg RJ, Jaffe HS, Hitchcock MJ, Drew WL.
    Adv Exp Med Biol; 1996 Jun 09; 394():105-15. PubMed ID: 8815677
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug.
    Cundy KC, Li ZH, Hitchcock MJ, Lee WA.
    Drug Metab Dispos; 1996 Jul 09; 24(7):738-44. PubMed ID: 8818570
    [Abstract] [Full Text] [Related]

  • 39. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
    Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC.
    J Infect Dis; 1995 Apr 09; 171(4):788-96. PubMed ID: 7706804
    [Abstract] [Full Text] [Related]

  • 40. A quantitative LC-MS/MS method for the determination of tissue brincidofovir and cidofovir diphosphate in a MuPyV-infected mouse model.
    Guzman BB, Schauer AP, Dunn JA, Cottrell ML, Sykes C.
    Biomed Chromatogr; 2021 May 09; 35(5):e5061. PubMed ID: 33398885
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.